The role of BRCA1 in non-small cell lung cancer

被引:7
|
作者
Gachechiladze, Mariam [1 ]
Skarda, Josef [1 ]
机构
[1] Palacky Univ Olomouc, Fac Med & Dent, Dept Clin & Mol Pathol, Olomouc, Czech Republic
来源
BIOMEDICAL PAPERS-OLOMOUC | 2012年 / 156卷 / 03期
关键词
BRCA1; non-small cell lung cancer; chemotherapy; RNA EXPRESSION LEVELS; PHASE-III; CISPLATIN; ERCC1; CHEMOTHERAPY; GEMCITABINE; DOCETAXEL; PLATINUM;
D O I
10.5507/bp.2012.049
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Background. BRCA1 (Breast cancer 1) was previously identified as a breast and ovarian cancer susceptibility gene, but recently gained a major scientific interest as a prognostic and/or predictive marker for various tumors, including non-small cell lung cancer (NSCLC), which is the leading cause of cancer related mortality in the world. We aimed to review the role of BRCA1 in NSCLC based on currently available literature. Methods. We performed the literature search in Pubmed database, using key words: BRCA1, non small cell lung cancer, chemotherapy, drug resistance. Articles published in English were selected for review. Results. Research papers are mainly focused on BRCA1 mRNA expression studies in response to DNA damaging chemotherapy. Several articles about genetic and epigenetic changes of BRCA1 in NSCLC were also available. Conclusions. BRCA1 is a multifunctional tumor supressor protein, which plays a key role in essential cellular processes and modulates the cellular response to cytotoxic chemotherapy. With the difference from breast and ovarian cancer, BRCA1 has no role in NSCLC cancerogenesis and mainly discussed as a promising genomic marker for customized chemotherapy in NSCLC patients.
引用
收藏
页码:200 / 203
页数:4
相关论文
共 50 条
  • [21] Personalized treatment in non-small cell lung cancer
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (04): : 377 - 386
  • [22] Advances in treatment for non-small cell lung cancer
    Price, Katharine A.
    Jett, James R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (07) : 792 - 794
  • [23] The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy
    Yang, Min
    Fan, Wei-fei
    Pu, Xiao-lin
    Meng, Li-juan
    Wang, Jun
    JOURNAL OF CHEMOTHERAPY, 2017, 29 (02) : 106 - 112
  • [24] Prognostic significance of BRCA1 and RASSF1A promoter hypermethylation in non-small cell lung cancer patients
    Gao, Weiwei
    Zhou, Zheng
    Liu, Ying
    Liu, Daijian
    Feng, Qingqing
    Xu, Yalai
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (08): : 8544 - 8549
  • [25] Management of stage IIIA non-small cell lung cancer (NSCLC) role of the chemotherapy
    Baudoux, Nathalie
    Friedlaender, Alex
    Addeo, Alfredo
    CURRENT CHALLENGES IN THORACIC SURGERY, 2022, 4
  • [26] Role of immunotherapy in locally advanced non-small cell lung cancer
    Levy, A.
    Doyen, J.
    Botticella, A.
    Bourdais, R.
    Achkar, S.
    Giraud, P.
    Du, C.
    Naltet, C.
    Lavaud, P.
    Besse, B.
    Pradere, P.
    Mercier, O.
    Caramella, C.
    Planchard, D.
    Deutsch, E.
    Le Pechoux, C.
    CANCER RADIOTHERAPIE, 2020, 24 (01): : 67 - 72
  • [27] The role of ifosfamide in non-small cell lung cancer (NSCLC) treatment
    Manegold, K
    EXPERIMENTAL ONCOLOGY, 1996, 18 (01): : 69 - 72
  • [28] The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Dunne, Elizabeth G.
    Fick, Cameron N.
    Isbell, James M.
    Chaft, Jamie E.
    Altorki, Nasser
    Park, Bernard J.
    Spicer, Jonathan
    Forde, Patrick M.
    Gomez, Daniel
    Iyengar, Puneeth
    Harpole Jr, David H.
    Stinchcombe, Thomas E.
    Liberman, Moishe
    Bott, Matthew J.
    Adusumilli, Prasad S.
    Huang, James
    Rocco, Gaetano
    Jones, David R.
    ANNALS OF THORACIC SURGERY, 2024, 118 (01) : 119 - 129
  • [29] The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
    Boland, William
    Bebb, Gwyn
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 289 - 298
  • [30] Doublet gemcitabine-platin in the treatment of non-small cell lung cancer
    Souquet, PJ
    Gerinière, L
    BULLETIN DU CANCER, 2002, 89 : S80 - S84